Alcoholic Cirrhosis
Conditions
Keywords
cirrhosis, alcohol
Brief summary
The purpose of this study is to determine if zinc therapy: (1) strengthens your intestine's defensive barrier preventing damaging substances from reaching your liver, (2) decreases liver injury (inflammation, oxidative stress, cell death) and scarring, and (3) improves your liver-related health. Based on our preliminary animal data and other published reports, we expect zinc therapy to achieve all of these goals. Zinc is affordable, available over the counter or by prescription, and has an excellent safety profile. Positive results from this study will show that zinc is a significant therapy for millions of Americans with alcoholic liver disease.
Detailed description
Two-thirds of Americans consume alcohol, and an estimated 14 million Americans are alcoholics. It has been estimated that 15%-30% of heavy drinkers develop advanced Alcoholic liver disease (ALD). The prevalence of ALD in the United States is conservatively estimated at 2 million persons. Nearly 50% of liver-related deaths and 30% of hepatocellular carcinomas in the US are due to alcoholic cirrhosis. Despite recent advances in our understanding of ALD, there is currently no FDA approved medication for any stage of ALD. Zinc sulfate is inexpensive, available over the counter, and has an excellent safety profile. If zinc positively influences the mechanisms postulated to play a role in human ALD, this affordable treatment would become relevant to millions of people worldwide.
Interventions
DIETARY_SUPPLEMENTZinc
DIETARY_SUPPLEMENTPlacebo
Sponsors
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
University of Louisville
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
1. Ability to provide informed consent. 2. Clinical diagnosis of alcoholic cirrhosis. 3. Between the ages of 18 years and 70 years. 4. Ability to attend all clinic visits and participate in monthly telephone calls. 5. Child-Pugh score of A or B.
Exclusion criteria
1. Allergy or intolerance to zinc sulfate. 2. Hospitalization within the previous 28 days. 3. Pregnancy. 4. Illicit drug use within the past 12 months. 5. Infection with hepatitis B, hepatitis C, or HIV. 6. Known or suspected cancer within the past 5 years. 7. Serum creatinine greater than 1.5 mg/dl within the past month. 8. Any severe chronic disease other than liver disease. 9. Impairment (slowness) of behavior, intelligence, and neuromuscular function which may indicate hepatic encephalopathy (slow or confused thinking due to your liver disease). 10. Participation in another clinical trial. 11. Any type of infection within the past month.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in clinical status | Baseline to 3 months | Whether the subject has improved clinically at time point. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Blood zinc levels | 0,3,6,12,24 months | — |
| Change in serum endotoxin levels | 0,3,6,12,24 months | Whether the subject has a change in the serum endotoxin levels. |
Countries
United States
Outcome results
None listed